Does the dose need to be adjusted in patients with renal or hepatic impairment?
No dosage adjustment is required in patients with mild renal impairment (CCr 50-80 mL/min) or mild or moderate hepatic impairment.6 In patients with moderate renal impairment (CCr 30-50 mL/min), the dose should be reduced to 4 mg once daily.6 RAPAFLO is contraindicated in patients with severe hepatic or renal impairment. 6 Back to top † Exercise caution during concominant use with anti-hypertensive agents and PDE-5 inhibitors and monitor patient for possible adverse events. patient for possible adverse events.
